Public Citizen Calls on FDA to Pull Gout Drug Due to CV Risk

Megan Brooks

June 27, 2018

The nonprofit advocacy group Public Citizen has asked the US Food and Drug Administration (FDA) to immediately pull the gout drug febuxostat (Uloric, Takeda Pharmaceuticals) from the market following results of a large postmarketing study that showed higher rates of fatal cardiovascular (CV) events and all-cause mortality in patients taking the drug. 

There is "overwhelming evidence that the serious cardiovascular harms of febuxostat outweigh any purported clinical benefit," the group writes in a citizen petition filed June 21.

The FDA initially rejected the new drug application for febuxostat twice, citing concerns over CV risks seen in initial clinical trials. The agency finally approved the drug in 2009 on the condition that Takeda conduct a large postmarket randomized clinical trial to further evaluate CV risks.

The results of that study, known as CARES, was published March 12 in the New England Journal of Medicine (NEJM) to coincide with presentation at the American College of Cardiology (ACC) 2018 Annual Scientific Session.

As reported by | Medscape Cardiology,  the CARES study compared the CV safety of febuxostat and allopurinol in more than 6100 patients at high CV risk who took the drugs for an average of 2.5 years.

The risk for CV events over the study period did not markedly differ between patients receiving febuxostat and those taking allopurinol. However, that was tempered by a secondary finding of significantly increased all-cause mortality, driven by CV deaths, in patients taking febuxostat compared with those taking allopurinol.

The FDA announced the main CARES outcomes in preliminary form  in November 2017 in a safety communication, which cautioned about an excess of "heart-related deaths and death from all causes" with febuxostat.

"The results of the FDA-mandated post-market trial now provide additional high-quality evidence of a causal link between treatment with febuxostat and an increased risk of death, particularly death from cardiovascular causes," Michael Carome, MD, director of Public Citizen's Health Research Group, said in a news release.

"The FDA almost certainly would have denied approval of febuxostat if data from this post-market trial had been available at the time of the initial submission," said Carome. "The only justifiable course of action to prevent further cardiovascular deaths is obvious: This medication must be removed from the US market immediately."

Kara Hoeger, corporate communications officer for Takeda Pharmaceuticals, said the company is aware of the petition and "declines to comment on it; the FDA will respond to Public Citizen's petition."

"Through presentation at ACC and publication in NEJM, we've been proactive in sharing CARES with the medical community as well as FDA — first notifying them following the initial data analysis in October," she said. "We've submitted the complete study data to the FDA and are working with them to conduct a comprehensive review of this data,"

Speaking with | Medscape Cardiology at the ACC meeting, Eileen Handberg, PhD, University of Florida, Gainesville, said there are compelling reasons to keep febuxostat available, given the lack of more definitive evidence of a significant hazard.

Many drugs with useful roles have shown signals of risk, said Handberg, who was not involved with the CARES trial.

If regulators were to pull them from the market on the basis of such signals, "then you'd take away a patient's ability to make an informed decision with their provider. The rheumatologists deal with a very chronically ill group of patients, and if either drug is doing well by them, are we going to remove it?" she added.

"Let's better understand the signal before we make that decision." If the risk can be identified, she said, then it can be up to patients and providers to decide whether to accept it.

Handberg discloses receiving research grants from Aastrom Biosciences, Amorcyte, Biocardia, Ccapricor, Cytori Therapeutics, Direct Flow Medical, Everyfit, Medtronic, Merck, Mesoblast, PCORI, and Sanofi Aventis; and unspecified relationships with Amgen, AstraZeneca, Boerhinger Ingleheim, Daiichi Sankyo, Gilead Sciences, Ionis, and Relypsa.

For more from | Medscape Cardiology, follow us on Twitter and Facebook


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.